Nail Debridement

Medicare covers nail debridement for documented mycotic nail infection when clinical findings (discoloration, onycholysis, subungual debris, thickening, or secondary skin infection) are present and, for toenails, when ambulation-related limitation, pain, or secondary infection from thickening/dystrophy is documented for ambulatory or non-ambulatory patients as specified. Appropriate antifungal therapy must be provided unless a documented contraindication exists, and local contractors/LCDs may further define reasonable and necessary circumstances for coverage.

"Clinical evidence of mycotic (fungal) infection of the nail demonstrated by discoloration, onycholysis, subungual debris, thickening, or secondary skin infection."

Sign up to see full coverage criteria, indications, and limitations.